Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment

Brain, Behavior, and Immunity

Volumn 43, Issue , 2015, Pages 198-204

  Isgren, Anniella ^a   Jakobsson, Joel ^a   Pålsson, Erik ^a   Ekman, Carl Johan ^b   Johansson, Anette G M ^b   Sellgren, Carl ^b   Blennow, Kaj ^a   Zetterberg, Henrik ^a,c   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic drugs; Biomarkers; Bipolar disorder; Cerebrospinal fluid; Cytokines; Interleukin 8; Lithium

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LITHIUM; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; CEREBROSPINAL FLUID; MIDDLE AGED;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; INTERLEUKIN-8; LITHIUM; MALE; MIDDLE AGED;

EID: 84919362798     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.10.001     Document Type: Article

References (59)

1. Andersson M., Alvarez-Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredrikson S., Gallo P., Grimaldi L.M., Gronning M., et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry 1994, 57:897-902.
2. Assarson E., Lundberg M., Holmquist G., Björkesten J., Thorsen S.B., Ekman D., Eriksson A., Rennel Dickens E., Ohlsson S., Edfeldt G., Andersson A.C., Lindstedt P., Stenvang J., Gullberg M., Fredriksson S. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 2014, 9(4):e95192.
3. Barbosa I.G., Huguet R.B., Mendonca V.A., Sousa L.P., Neves F.S., Bauer M.E., Teixeira A.L. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261:139-143.
4. Barbosa I.G., Rocha N.P., Bauer M.E., de Miranda A.S., Huguet R.B., Reis H.J., Zunszain P.A., Horowitz M.A., Pariante C.M., Teixeira A.L. Chemokines in bipolar disorder: trait or state?. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:159-165.
5. Belmaker R.H. Bipolar disorder. N. Engl. J. Med. 2004, 351:476-486.
6. Berman A.H., Bergman H., Palmstierna T., Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur. Addict. Res. 2005, 11:22-31.
7. Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 2009, 23:1079-1082.
8. Bromander S., Anckarsater R., Kristiansson M., Blennow K., Zetterberg H., Anckarsater H., Wass C.E. Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. J. Neuroinflammation 2012, 9:242.
9. Chen M.L., Tsai T.C., Wang L.K., Lin Y.Y., Tsai Y.M., Lee M.C., Tsai F.M. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-alpha-directed cell apoptosis in neutrophils. Int. Immunopharmacol. 2012, 12:197-204.
10. Chen M.L., Wu S., Tsai T.C., Wang L.K., Tsai F.M. Regulation of macrophage immune responses by antipsychotic drugs. Immunopharmacol. Immunotoxicol. 2013, 35:573-580.
11. Cruz N.G., Sousa L.P., Sousa M.O., Pietrani N.T., Fernandes A.P., Gomes K.B. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2013, 99(2):85-92.
12. Davey K.J., O'Mahony S.M., Schellekens H., O'Sullivan O., Bienenstock J., Cotter P.D., Dinan T.G., Cryan J.F. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology 2012, 221:155-169.
13. Di Nicola M., Cattaneo A., Hepgul N., Di Forti M., Aitchison K.J., Janiri L., Murray R.M., Dazzan P., Pariante C.M., Mondelli V. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013, 31:90-95.
14. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., Berghout A., Nolen W.A., Drexhage H.A. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011, 25:1206-1213.
15. Dugue B., Leppanen E., Grasbeck R. Preanalytical factors and the measurement of cytokines in human subjects. Int J Clin Lab. Res. 1996, 26:99-105.
16. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
17. Giovannelli A., Limatola C., Ragozzino D., Mileo A.M., Ruggieri A., Ciotti M.T., Mercanti D., Santoni A., Eusebi F. CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. J. Neuroimmunol. 1998, 92:122-132.
18. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090.
19. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 1999, 33:407-418.
20. Hallberg L., Janelidze S., Engstrom G., Wisen A.G., Westrin A., Brundin L. Exercise-induced release of cytokines in patients with major depressive disorder. J. Affect. Disord. 2010, 126:262-267.
21. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
22. Hope S., Dieset I., Agartz I., Steen N.E., Ueland T., Melle I., Aukrust P., Andreassen O.A. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res. 2011, 45:1608-1616.
23. Jakobsson J., Zetterberg H., Blennow K., Johan Ekman C., Johansson A.G., Landen M. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 2013, 38:664-672.
24. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104:91-95.
25. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee S.W., Leonard B.E., Steinbusch H.W. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004, 129:267-272.
26. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., Licinio J. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 2002, 7:1107-1114.
27. Kohut M.L., McCann D.A., Russell D.W., Konopka D.N., Cunnick J.E., Franke W.D., Castillo M.C., Reighard A.E., Vanderah E. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav. Immun. 2006, 20:201-209.
28. Kossmann T., Stahel P.F., Lenzlinger P.M., Redl H., Dubs R.W., Trentz O., Schlag G., Morganti-Kossmann M.C. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J. Cereb. Blood Flow Metab. 1997, 17:280-289.
29. Leckman J.F., Sholomskas D., Thompson W.D., Belanger A., Weissman M.M. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch. Gen. Psychiatry 1982, 39:879-883.
30. Lee Y.B., Nagai A., Kim S.U. Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 2002, 69:94-103.
31. Lehto S.M., Niskanen L., Herzig K.H., Tolmunen T., Huotari A., Viinamaki H., Koivumaa-Honkanen H., Honkalampi K., Ruotsalainen H., Hintikka J. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology 2010, 35:226-232.
32. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Altamura C.A. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002, 54:281-291.
33. Maes M., Song C., Lin A.H., Pioli R., Kenis G., Kubera M., Bosmans E. In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology 1999, 143:401-407.
34. Maier B., Laurer H.L., Rose S., Buurman W.A., Marzi I. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J. Neurotrauma 2005, 22:822-835.
35. Malekzadeh A., de Groot V., Beckerman H., van Oosten B.W., Blankenstein M.A., Teunissen C. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases (San Diego, Calif.). Methods 2012, 56:508-513.
36. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 2009, 33:355-366.
37. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol. Psychiatry 2013, 74:15-25.
38. Munkholm K., Brauner J.V., Kessing L.V., Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 2013, 47:1119-1133.
39. Munkholm K., Vinberg M., Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J. Affect. Disord. 2013, 144:16-27.
40. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52:145-176.
41. Nemeth Z.H., Deitch E.A., Szabo C., Fekete Z., Hauser C.J., Hasko G. Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells. J. Biol. Chem. 2002, 277:7713-7719.
42. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90:263-267.
43. Rapaport M.H., Manji H.K. The effects of lithium on ex vivo cytokine production. Biol. Psychiatry 2001, 50:217-224.
44. Roy M.A., Lanctot G., Merette C., Cliche D., Fournier J.P., Boutin P., Rodrigue C., Charron L., Turgeon M., Hamel M., Montgrain N., Nicole L., Pires A., Wallot H., Ponton A.M., Garneau Y., Dion C., Lavallee J.C., Potvin A., Szatmari P., Maziade M. Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. Am. J. Psychiatry 1997, 154:1726-1733.
45. Ryden E., Thase M.E., Straht D., Aberg-Wistedt A., Bejerot S., Landen M. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr. Scand. 2009, 120:239-246.
46. Sachs G.S., Thase M.E., Otto M.W., Bauer M., Miklowitz D., Wisniewski S.R., Lavori P., Lebowitz B., Rudorfer M., Frank E., Nierenberg A.A., Fava M., Bowden C., Ketter T., Marangell L., Calabrese J., Kupfer D., Rosenbaum J.F. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 2003, 53:1028-1042.
47. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993, 88:791-804.
48. Semple B.D., Kossmann T., Morganti-Kossmann M.C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab. 2010, 30:459-473.
49. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33.
50. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16:751-762.
51. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur. Neuropsychopharmacol. 2008, 18:230-233.
52. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Whelan A., Cosyns P., de Jongh R., Maes M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 1998, 49:211-219.
53. Stuart M.J., Baune B.T. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci. Biobehav. Rev. 2014, 42:93-115.
54. Subileau E.A., Rezaie P., Davies H.A., Colyer F.M., Greenwood J., Male D.K., Romero I.A. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68:227-240.
55. Söderlund J., Olsson S.K., Samuelsson M., Walther-Jallow L., Johansson C., Erhardt S., Landen M., Engberg G. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J. Psychiatry Neurosci. 2011, 36:114-118.
56. Warnberg J., Cunningham K., Romeo J., Marcos A. Physical activity, exercise and low-grade systemic inflammation. Proc. Nutr. Soc. 2010, 69:400-406.
57. Yao Y., Tsirka S.E. Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell. Mol. Life Sci. 2014, 71:683-697.
58. Zetterberg H., Jakobsson J., Redsater M., Andreasson U., Palsson E., Ekman C.J., Sellgren C., Johansson A.G., Blennow K., Landen M. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. 2014, 217:143-146.
59. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65:940-947.